Telesis Bio, Inc. (TBIO)

0,3300 -0,0236 (-6,67%) Alla chiusura: 04:00PM EDT

Telesis Bio, Inc.

10431 Wateridge Circle
Suite 150
San Diego, CA 92121-2993
United States
858 228 4115
https://telesisbio.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 137

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Todd R. Nelson MBA, Ph.D.	Founder & Director	924,38k	N/D	1967
Mr. Daniel G. Gibson Ph.D.	Chief Technology Officer	590,37k	N/D	1977
Mr. Robert H. Cutler	Chief Legal Officer	568,58k	N/D	1968
Mr. Eric Esser	President, CEO, COO & Director	N/D	N/D	1969
Mr. William J. Kullback	Chief Financial Officer	N/D	N/D	1960
Ms. Jen Carroll	Vice President of Investor Relations	N/D	N/D	N/D
Mr. Decky Goodrich M.B.A.	Senior Vice President of Corporate Development	N/D	N/D	N/D
Richard Lepke	Director of Investor Relations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Telesis Bio, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.